B
Belén Atienza-Mateo
Researcher at University of Cantabria
Publications - 89
Citations - 662
Belén Atienza-Mateo is an academic researcher from University of Cantabria. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 57 publications receiving 266 citations.
Papers
More filters
Journal ArticleDOI
Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Belén Atienza-Mateo,Vanesa Calvo-Río,Emma Beltrán,Lucía Martínez-Costa,Elia Valls-Pascual,Marisa Hernández-Garfella,Antonio Atanes,Miguel Cordero-Coma,Joan M. Nolla,Carmen Carrasco-Cubero,Javier Loricera,María Carmen González-Vela,N. Vegas-Revenga,C. Fernández-Díaz,R. Demetrio-Pablo,L Domínguez-Casas,José Luis Martín-Varillas,Natalia Palmou-Fontana,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +20 more
TL;DR: TCZ yielded rapid and maintained improvement in all ocular parameters of the patients, with complete remission in eight of them, but this was not the case for the extraocular manifestations, since TCZ was only effective in three of them.
Journal ArticleDOI
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
N. Vegas-Revenga,Vanesa Calvo-Río,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Emma Beltrán,Elia Valls Pascual,David Díaz-Valle,Gisela Díaz-Cordovés,Marisa Hernández-Garfella,Lucía Martínez-Costa,Inmaculada Calvo,Antonio Atanes,L. Linares,Consuelo Modesto,Carmen González-Vela,R. Demetrio-Pablo,Elena Aurrecoechea,Miguel Cordero,L Domínguez-Casas,Belén Atienza-Mateo,José Luis Martín-Varillas,Javier Loricera,Natalia Palmou-Fontana,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +26 more
TL;DR: Macular thickness is reduced following administration of tocilizumab (TCZ) in refractory uveitis-related CME, a statistically significant improvement in macular thickness compared to baseline.
Journal ArticleDOI
Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease
José Luis Martín-Varillas,Vanesa Calvo-Río,Emma Beltrán,Juan Sánchez-Bursón,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Marisa Hernandez Garfella,Elia Valls Pascual,Lucía Martínez-Costa,Agusti Sellas-Fernández,Miguel Cordero-Coma,Manuel Díaz-Llopis,Roberto Gallego,David Salom,Norberto Ortego,José L. García-Serrano,José-Luis Callejas-Rubio,José M. Herreras,Ángel García-Aparicio,O. Maíz,Ana Blanco,Ignacio García-De La Torre,David Díaz-Valle,Esperanza Pato,Elena Aurrecoechea,M.A. Caracuel,Fernando Gamero,Enrique Minguez,Carmen Carrasco-Cubero,Alejandro Olivé,J. Vazquez,Oscar Ruiz-Moreno,Javier Manero,Santiago Muñoz-Fernández,Myriam Gandía Martinez,Esteban Rubio-Romero,F. Javier Toyos-Sáenz de Miera,Francisco Javier López Longo,Joan M. Nolla,Marcelino Revenga,Carmen González-Vela,Javier Loricera,Belén Atienza-Mateo,R. Demetrio-Pablo,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +47 more
TL;DR: ADA optimization in BD uveitis refractory to conventional therapy is effective, safe, and cost-effective, and the mean ADA treatment costs were lower in the optimized group than in the nonoptimized group.
Journal ArticleDOI
Tocilizumab for the treatment of adult-onset Still's disease.
Santos Castañeda,Dolores Martínez-Quintanilla,José Luis Martín-Varillas,Noelia García-Castañeda,Belén Atienza-Mateo,Miguel A. González-Gay +5 more
TL;DR: Tocilizumab, the only anti-IL-6-receptor antagonist currently available for AOSd, has proved to be effective for the management of refractory AOSD patients, including those with life-threatening complications.
Journal ArticleDOI
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Esther F Vicente-Rabaneda,Belén Atienza-Mateo,Ricardo Blanco,Lorenzo Cavagna,Julio Ancochea,Santos Castañeda,Miguel A. González-Gay,Miguel A. González-Gay +7 more
TL;DR: Current evidence suggests that ABA may be a plausible alternative to treat RA patients with ILD and was associated with a 90% reduction in the relative risk of deterioration of ILD at 24 months of follow-up compared to TNFi and csDMARDs.